Silexion Therapeutics Corp received positive feedback from the German Federal Institute for Drugs and Medical Devices, supporting the proposed design of its Phase 2/3 clinical trial for SIL204, a treatment for locally advanced pancreatic cancer. The company plans to complete regulatory submissions in Israel by the end of Q4 2025 and in Germany in Q1 2026. Silexion remains on track to initiate the Phase 2/3 trial in the first half of 2026 pending regulatory approval. The company is dedicated to advancing innovative treatments for KRAS-driven cancers and is committed to addressing critical unmet needs in oncology.

Read more at GlobeNewswire: Silexion Therapeutics Receives Positive Feedback from